Browse Articles

Discover research articles across all indexed journals

Bioinspired Liquid Pockets with Externally Induced Internal Microscale Flow

Advanced Materials Lian Xu, Feng Wu, Yigang Shen et al. Feb 01, 2025 DOI: 10.1002/adma.202415661

AbstractThe gastric mucosal barrier, through its gastric pits, serves as a pathway for secretions, ensuring that mucus produced by the gastric glands is transferred to the gastric lumen, providing stable protection. Here a bioinspired liquid pockets material is shown, composed of a thermo‐driven hydrogel that acts as an external activation unit to release interflowing liquid responsively, and porous matrices that serve as interconnected pockets to transfer it, enabling controlled internal flow and adaptive barrier functionality. Experiments and theoretical analysis demonstrate the stability and regulatory mechanisms of these liquid pockets, based on the interconnected pockets between the external activation unit and internal fluid flow. It exhibits a new pathway for regulating microscale flow at responsive material interfaces, enabling applications from sequential drug release, self‐cleaning, and antifouling to anti‐swelling. These unique capabilities address long‐standing challenges in microscale flow control, with potential impacts in diverse fields including microfluidics, drug delivery, medical devices, 3D printing, and beyond.

Retrospective analysis of HAIP therapy in metastatic colorectal cancer: Efficacy, safety, and prognostic factors.

Journal of Clinical Oncology Matthew Sawyer, Amy Little Jones, Anna Moscowitz et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.126

126 Background: HAIP (hepatic arterial infusion pump) therapy is a promising intervention for metastatic colorectal cancer (mCRC) with liver metastases, addressing significant challenges in management and prognosis. It offers targeted treatment to maximize efficacy while minimizing systemic toxicity. We present a retrospective analysis of patients with metastatic colorectal adenocarcinoma treated with HAIP therapy at an academic center and safety net hospital. Methods: Patients with mCRC and hepatic metastasis who received at least one HAIP floxuridine (FUDR) cycle from 2013 to 2023 were included. Baseline data, including demographics, tumor characteristics, and treatment history, were collected pre-HAIP. The main outcome was overall survival (OS) post-pump placement, with secondary outcomes being real-world progression-free survival (rwPFS) and HAIP-related complications. Results: In total, 88 patients were evaluated for inclusion, of whom 63 met inclusion criteria and were included for analysis. The median age of included patients was 46 years (interquartile range (IQR) 41-57) and 54% were male. Prior to HAIP, 38 (60%) of patients received one line of systemic therapy, while 18 (29%) had two. The median OS from HAIP placement was 28.0 months (95% CI 21.9-NR) and median rwPFS was 11.2 months (95% CI 7.1-16.1). Baseline bilirubin, KRAS mutant status, and CEA were associated with OS in the multivariate cox model. The most common complication from HAIP placement was hematoma (n=4, 6.3%), followed by pump infection (n=2, 3.2%). Grade 3 toxicities from FUDR infusion were infrequent, involving alkaline phosphatase (n=6), AST or ALT elevation (n=3), bilirubin increase (n=2), and platelet count decrease (n=1). Conclusions: HAIP treatment is associated with durable responses and few complications, making it well-tolerated by patients. For individuals with colorectal cancer and hepatic metastases, HAIP chemotherapy using FUDR presents a viable and effective treatment option, potentially improving overall outcomes and quality of life. Further prospective and randomized work may establish the role for HAIP in mCRC with liver metastases.

Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.

Journal of Clinical Oncology Chenchen Wang, Mingzhu Huang, Yuedi Dai et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.461

461 Background: For unresectable locally advanced or metastatic HER2-negative gastric cancer (GC), the combination of chemotherapy with immunotherapy, specifically PD-1 inhibitors, has emerged as a new standard of care in first-line treatment of advanced GC, but the patients’ outcomes remain poor. Early clinical studies investigating the combination of immunotherapy with anti-angiogenic drugs have demonstrated favorable efficacy. Therefore, it is worth exploring whether the addition of fruquintinib, a potent VEGFR-1,2,3 inhibitor, to the combination of PD-1 inhibitor and chemotherapy can further enhance the survival benefits for patients with unresectable locally advanced or metastatic HER2-negative GC. Methods: This is an open-label, single-center clinical study. The enrolled patients were all no less than 18 years old with HER2 negative locally advanced unresectable or metastatic gastric or gastrooesophageal junction adenocarcinoma, without any systemic anticancer treatment for advanced disease. Eligible patients received 6 cycles of combined first line treatment with fuquinitinib (4mg daily, d1-14, q3w, oral) combined with PD-1 inhibitor (sintilimab 200mg or nivolumab 360mg intravenously q3w) and chemotherapy (XELOX or SOX) regimen. The following maintenance treatment was fuquinitinib combined with PD-1 inhibitor and S-1/capecitabine until disease progression or intolerable toxicity. The primary endpoint was progress free survival (PFS). Secondary endpoints included objective response rate (ORR), overall survival (OS), duration of response (DoR), disease control rate (DCR) and safety. Results: At the cutoff date on Sep 18, 2024, a total of 27 patients were enrolled and received at least one dose of treatment. 23 patients had received the response evaluation, with an ORR of 60.9% (14/23; 95%CI 38.5-80.3) and DCR of 100% (23/23 95%CI 85.2-100.0). In the intention to treatment (ITT) population, the median PFS was 9.79 months (95% CI 5.29-NA). Safety profile indicated that 22.2% (6/27) experienced grade≥3 adverse events. The most common grade ≥ 3 adverse reactions mainly include neutropenia (7.4%, 2/27) and thrombocytopenia (7.4%%, 2/27). Conclusions: The combination of fruquintinib and chemotherapy with PD-1 blockade in the first-line treatment for unresectable locally advanced or metastatic HER2-negative GC had shown promising efficacy and acceptable safety profile. Enrollment in the trials is still ongoing. Clinical trial information: NCT06158919 .

Preclinical development of the lipid nanoparticle–based mRNA vaccine with multiple natural T cell epitopes for pancreatic cancer.

Journal of Clinical Oncology Josephine Chang, Kevin Zheng, Yiming Li et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.752

752 Background: Immunotherapy has recently emerged as a promising avenue in cancer treatment; however, its effectiveness on pancreatic ductal adenocarcinoma (PDAC) is hindered by the lack of effector T cells in the tumor microenvironment. One of the strategies to overcome the resistance of PDAC to immunotherapy involves identifying immunogenic tumor-associated and specific antigens for the development of personalized cancer vaccines. The mRNA platform has become an attractive platform for antigen presentation. The delivery of mRNA cancer vaccines via lipid nanoparticles (LNPs) enables intracellular delivery and controlled release of the payload, offering improved vaccine efficacy. However, mRNA vaccines presenting human T cell epitopes often lack a preclinical model for antitumor immune efficacy testing. Methods: A syngeneic mouse model of PDACs was established by implanting KPC tumor cells into the livers by hemispleen surgery. mRNA vaccine expressing five 25-mer peptide regions were synthesized. Two mouse CD8+ T cell epitopes were predicted. Their MHC binding was tested by the T2 binding assay. CD8+ T cells specific for these two epitopes were examined by ELISpot assays and were quantified by ImmunoSpot ELISpot Reader to identify changes in IFN-g secretion. Results: Using mass spectrometry analysis, we successfully identified natural HLA class I and class II-binding epitopes in the neoplastic tissues of human PDACs. For the design of mRNA vaccine, we chose five 25-mer peptide regions that each contains both class I and class II epitopes punctuated by AAY and GPGPG linkers and followed by an MITD sequence, which all aim to improve the efficiency of antigen presentation to dendritic cells. Using NetMHC, we predicted H2Kb or H2Db-binding epitopes LYPFPLAL and SMVQMTFL, within these five human peptide regions. The T2 binding assay showed a lack of evident binding of both peptides to the T2-Kb or T2-Db cells. However, the ELISpot assay showed that LYPFPLAL, but not SMVQMTFL, can induce the IFN-g expression from CD8+ T cells derived from splenocytes of the KPC tumor mice vaccinated by a peptide vaccine containing both peptides. Therefore, this result confirmed that LYPFPLAL is a mouse CD8+ T cell epitope and can be used to monitor antigen-specific CD8+ T cell response in response to the mRNA vaccine treatment in the syngeneic mouse model of PDACs. Conclusions: Antitumor efficacy of our above-designed mRNA vaccine can be tested in the syngeneic mouse hemispleen model of KPC tumors. Mouse LYPFPLAL epitope-specific CD8+ T cell response can serve as a surrogate marker for the antitumor efficacy of this mRNA vaccine in mouse models for PDAC.

Single‐Cell Isolation Chip Integrated with Multicolor Barcode Array for High‐Throughput Single‐Cell Exosome Profiling in Tissue Samples (Adv. Mater. 5/2025)

Advanced Materials Chao Wang, Yu Zhang, Jianbo Wang et al. Feb 01, 2025 DOI: 10.1002/adma.202570038

Transforming Plastics to Single Atom Catalysts for Peroxymonosulfate Activation: Axial Chloride Coordination Intensified Electron Transfer Pathway

Advanced Materials Shiying Ren, Yantao Wang, Lei Shi et al. Feb 01, 2025 DOI: 10.1002/adma.202415339

AbstractTransforming plastics into single‐atom catalysts is a promising strategy for upcycling waste plastics into value‐added functional materials. Herein, a graphene‐based single‐atom catalyst with atomically dispersed FeN4Cl sites (Fe─N/Cl─C) is produced from high‐density polyethylene wastes via one‐pot catalytic pyrolysis. The Fe─N/Cl─C catalyst exhibited much higher turnover frequency and surface area normalized activity (Kac) compared with the Fe─N─C catalyst without axial Cl modulation. Both experiments and density functional theory (DFT) computations demonstrated that the axial incorporation of chloride fine‐tuned the coordination environment of FeN4 sites and enhanced peroxymonosulfate (PMS) activation because of improved conductivity and modulated spin state. In situ, Raman, and infrared spectroscopic techniques revealed that PMS is activated by the Fe─N/Cl─C catalyst through an electron transfer process. The formation of a key PMS* intermediate at the Fe site effectively elevated the redox capacity of the catalyst surface to realize a fast degradation of diverse pollutants. The non‐radical oxidation manner secures high selectivity toward target pollutants and high chemical utilization efficiency. A continuous operation in a column reactor also demonstrated the high efficiency and stability of the (Fe─N/Cl─C + PMS) system for practical water treatment.

Efficacy and safety of HER2-targeted therapies in biliary tract cancer: A systematic review and meta-analysis of early phase clinical trials.

Journal of Clinical Oncology Parth Sharma, Mangesh Kritya, Priyanka Sharma et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.599

599 Background: Biliary tract cancers (BTC) are a rare type of gastrointestinal malignancy, often presenting in advanced stages and associated with a dismal prognosis. BTC are frequently resistant to conventional chemotherapy, with novel targeted therapies playing a pivotal role in overcoming this challenge. HER2 has recently emerged as an important actionable target in patients with BTC. We aim to evaluate the efficacy and safety of HER2 -directed monoclonal antibodies (MOAs), bispecific antibodies, antibody-drug conjugates (ADCs), and their combinations in BTC. Methods: A systematic literature search was conducted on PubMed, Embase, and Cochrane Central Register of Controlled Trials for clinical trials investigating HER2 -directed MOAs, bispecific antibodies, ADCs, and their combinations in BTC. The study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. A random effects model was used to pool the outcomes along with 95% confidence intervals (CI). Statistical analyses were performed using program R version 4.4.1. Results: We included 12 clinical trials with three Phase I and nine Phase II trials. The pooled ORR (objective/overall response rate) was 35.5% (95% CI: 26.2-45.3, I 2 : 69%), and the DCR (disease control rate) was 72.2% (95% CI: 65.3-78.8, I 2 : 37%). The median follow-up period for DCR was four months. Trastuzumab, in combination with gemcitabine-cisplatin as first-line therapy, had the highest median progression-free survival of 7 months (95% CI: 6.2-7.8), whereas the combination of trastuzumab and tucatinib had the longest median overall survival 15.5 months (90% CI: 6.5-16.7) reported. The most common treatment-related ≥grade 3 adverse events reported across the cohort were anemia and neutropenia. Three cases of confirmed grade 5 interstitial lung disease were reported in patients who received trastuzumab deruxtecan. Clinical trials included in this study are summarized in the table. Conclusions: Advances in precision oncology and the emergence of novel targeted therapies have revolutionized cancer management. HER2 -directed therapies have shown promising results for patients inflicted with BTC having HER2 alterations in the early phase clinical trials. Further larger studies are awaited to explore the efficacy of HER2 -directed therapies in BTC. Clinical trials of HER2 -directed therapies in BTC. HER2-directed therapy Number of clinical trials Total number of BTC participants ORR, in % (95% CI) DCR, in % (95% CI) Trastuzumab + chemo 2 124 43.2 (19.4-68.8) 80 (72.3-86.7) Trastuzumab + pertuzumab 2 45 20.9 (9.1-35.3) 53.4 (37.8-68.8) Trastuzumab deruxtecan 4 84 27.2 (6.9-52.6) 71.9 (58.4-84) Trastuzumab + tucatinib 1 30 46.7 (28.5-65.5) 76.7 (57.7-89.7) Zanidatamab 2 101 40.5 (30.9-50.4) 67.6 (57.9-76.6) SHR-A1811 1 16 56.3 (29.9-80.2) 81.3 (54.4-96)

A mixed methods evaluation of the Canopy Cancer Collective’s implementation of network-wide screening initiative in 2023.

Journal of Clinical Oncology Priya Pathak, Emily J Martin, Elizabeth Ann Kvale et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.709

709 Background: The Canopy Cancer Collective, a Learning Health Network (LHN) comprised of 14 pancreatic cancer centers across the U.S., set ambitious goals in 2023 to improve screening rates across four key areas: clinical trial screening (from a baseline of 30% to 100%), assessment of enzyme replacement (37% to 100%), goals of care discussions (57% to 100%), and palliative care screening (30% to 100%). This study aimed to identify the barriers and facilitators influencing the implementation of these screening aims, with the goal of developing informed, actionable recommendations for future implementation efforts. Methods: Throughout 2023, data were gathered from monthly assessments completed by site coordinators and quality improvement coaches at each of the 14 centers. These assessments captured insights into planning, implementation, and challenges related to the screening aims. Additionally, a comprehensive site assessment conducted in October 2023 was analyzed. We employed content analysis to identify the key factors influencing the implementation process, with percentage improvements in screening aims documented. Results: A total of 128 assessments were reviewed. The most common barriers identified were insufficient personnel and time for screening implementation (n=7), delayed responses and lack of engagement from supporting teams (n=6), unanticipated delays and logistical barriers to the procedures (n=6), recruitment challenges (n=3), and changes in the staff or management (n=5). Facilitators that supported implementation included: identification and testing of patient-centered strategies for implementation of screening (n=11), team expansion (n=8), consistent data collection and sharing through the LHN database (n=7), launching of other initiatives tailored to institutional needs (n=5), and collaboration between teams within or across institutions (n=4). Among the barriers to form ideal interprofessional composition, resource shortages (n=7), provider shortages (n=6), and coordination difficulties (n=5) were included. By January 2024, the network’s screening rates had improved significantly: 92% for clinical trial, 87% for enzyme need and palliative care each, and 97% for goals of care. Conclusions: While common challenges such as staffing limitations and logistical barriers posed obstacles, facilitators like patient-centered strategies, team growth, and improved collaboration were key to the successful implementation of the screening aims. These findings offer actionable insights for enhancing future implementation efforts, with a focus on addressing resource limitations and fostering team engagement. Moving forward, we plan to assess the outcomes of these screening initiatives to examine their impact on patient care and evaluate the perceptions of site on utilization of implementation strategies to promote its adoption.

Safety, efficacy, and outcomes of 90-yttrium radioembolization in combination with immune checkpoint inhibitors as a definitive first-line treatment approach in non-surgical hepatocellular carcinoma.

Journal of Clinical Oncology Alexandre Grahovac, Tyler Sandow, Jonathan Mizrahi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.617

617 Background: Immune checkpoint inhibitors (ICI) have emerged as first line therapy for advanced-stage hepatocellular carcinoma (HCC). However, response rates remain modest (<20%). Combination treatments offer potential to improve initial response rates while extending duration of response. While early studies of 90 Yttrium transarterial radioembolization ( 90 Y)-ICI showed fewer adverse events (AE) and improved objective responses (OR) (30-40%), there were no improvements in time to progression (TTP) and overall survival (OS). This study evaluates safety, efficacy, and outcomes of first line 90 Y-ICI while evaluating the role of ICI regimen and treatment sequencing. Methods: A retrospective, multi-center study was conducted in BCLC A-C stage HCC patients (ECOG 0-1) receiving first line 90 Y-ICI with atezolizumab/bevacizumab (A+B) or tremelimumab/durvalumab (STRIDE). Treatment response was recorded at 90 Y follow-up. TTP, progression-free survival (PFS), and OS were primary endpoints, with AE and safety as secondary outcomes. Results: The study included 40 patients receiving 90 Y-ICI from 2021–2024, with a median follow-up of 12 months. The cohort was predominantly Child-Pugh A (96%) with HCV-related cirrhosis (76%), BCLC-C stage (51%), and a median target HCC size of 7.7 cm (IQR, 6-11 cm). Grade 3-4 AEs occurred in 15 patients (37%), leading to steroid use (12, 29%), treatment delays (13, 31%), or discontinuation (4, 10%). The first cycle target OR rate was 82% (32/39), with a 51% (20/39) complete response (CR) rate. The first cycle overall OR was 59% (23/39), with a 41% (16/39) CR rate. No significant differences were found in adverse events, delays, or discontinuations based on sequencing or regimen. Sequencing had no significant effect on target or overall OR with no downstream effect on TTP (P = 0.968) or PFS (P = 0.906). Similarly, there was no effect of ICI regimen on OR, TTP (P = 0.813) or PFS (P = 0.904), although the data trended toward higher response rates with the STRIDE regimen. Log-rank analysis revealed target CR was associated with improved TTP (P = 0.004) and PFS (P = 0.009), but not OS (P = 0.237). Achieving an overall CR was associated with further improvements in TTP (P < 0.001) and PFS (P < 0.001). The cohort 2-year OS was 55% with median OS not yet reached. Conclusions: First line 90 Y-ICI therapy in BCLC A-C stage HCC is an effective treatment strategy with AEs in the expected range of systemic therapy and low rates of treatment discontinuation. Sequencing and ICI regimen did not significantly impact AEs or treatment outcomes. However, patients achieving CR showed significantly improved TTP and PFS. Although follow-up is limited, these findings suggest achieving CR is key to optimal long-term outcomes. We anticipate long-term follow-up will demonstrate an OS benefit linked to first line CR rate.

Near‐Infrared Luminescent Imaging‐Based 3D QR Cube Platform for Spatial Information Storage and Security (Adv. Mater. 6/2025)

Advanced Materials Sohyung Kim, Jiheon Lim, Suyeon Kim et al. Feb 01, 2025 DOI: 10.1002/adma.202570049

Plasma–Liquid‐Induced Synthesis of Scandium–Metalloporphyrin Frameworks for Boosted Sensing and Photosensitization

Advanced Materials Zhankuo Zhang, Zhanxin Liu, Xueshan Chen et al. Feb 01, 2025 DOI: 10.1002/adma.202412071

Abstract Inserting metal ions into the porphyrin ring is one of the primary strategies to enhance the properties of porphyrin‐based metal–organic frameworks (MOFs). However, the straightforward, rapid, and energy‐efficient synthesis of porphyrin‐based MOFs with high metallization for the porphyrin ring remains challenging. Herein, a solution anode glow discharge (SAGD) microplasma is presented for the one‐step synthesis of scandium‐metalloporphyrin frameworks (ScMPFs). The substantial number of electrons provided by the plasma–liquid interface not only accelerated the rapid nucleation and growth of MOFs but also promoted the incorporation of scandium (Sc 3+ ), which has a small ionic radius and strong coordination ability, into the N atoms in the porphyrin ring, and enhanced the metallization of MOFs. The sufficient Sc 3+ in frameworks inhibited the recombination of electron–hole pairs, resulting in boosted reactive oxygen species yield and a low fluorescence background of MOFs. Consequently, the ScMPFs are employed for the sensitive and rapid detection of F − in water with a detection limit of 0.24 µ m and for efficient bacteriostasis at low doses (10 µg mL −1 , 12 mW cm −2 light irradiation for 10 min).

Influence of preoperative Lynch syndrome diagnosis on surgery in patients with colorectal cancer.

Journal of Clinical Oncology Mohammad Ali Abbass, Sarah M. Nielsen Young, Emily M. Russell et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.94

94 Background: Lynch Syndrome (LS) can guide surgery for colorectal cancer (CRC), particularly for MLH1/MSH2 carriers, who may benefit from extended procedures: total colectomy (TC) or total proctocolectomy (TP). We investigated timing of germline genetic testing (GGT) and surgical approach in patients (pts) with LS and CRC. Methods: Integrated GGT (Labcorp, formerly Invitae Corp.) and insurance claims (Komodo Healthcare Map) data for adult pts with non-metastatic colon (CC) or rectal (RC) cancer and CRC surgery from 2015-23, ≥ 6 months of claims pre-CRC diagnosis, and GGT for EPCAM, MLH1, MSH2, MSH6, and PMS2 . Χ 2 and t tests and multivariable logistic regression compared GGT results and surgical approach. Results: Of 1616 CRC pts (1553 CC, 63 RC), 15% were LS positive (15% CC, 11% RC). Compared to pts with negative GGT, pts with LS were more likely male, Black, younger at diagnosis and GGT, to have family history of GI/any cancer and to have GGT pre-CRC surgery. Of 129 LS pts with CC and MLH1/MSH2/EPCAM, 41 (32%) had GGT pre-surgery and 20/41 (49%) had TC/TP (Table). 5/6 (83%) of the corresponding RC pts had GGT pre-surgery and 3/5 (60%) had TP. 88 CC MLH1 / MSH2 / EPCAM pts had GGT post-surgery and 17/88 (19%) had TC/TP. 1 MLH1 / MSH2 / EPCAM RC patient had GGT post-surgery and 0 had TP. More CC pts had TC/TP than RC pts (p<0.001). Compared to pts with negative GGT, pts with LS and CRC were more likely to have TC/TP (21% vs. 6%, p<0.001), particularly with GGT pre-surgery (43% vs. 13%, p<0.001). RC LS pts with GGT pre-surgery had shorter mean months from GGT to surgery than pts with negative GGT (6 vs 14, p=0.026). CC pts with MLH1 or MSH2/EPCAM and GGT pre-surgery had higher odds of undergoing TC/TP (odds ratio (OR): 6, confidence interval (CI): 3-10; OR: 7, CI: 4-14; OR: 4, CI: 2-6) than pts with negative or post-surgery GGT. Conclusions: GGT performed pre-surgery for a new diagnosis of CRC was more likely to result in extended procedures, especially in MLH1/MSH2/EPCAM carriers. More data in RC is needed to better understand the influence of GGT on surgical approach. CC surgery type and timing in relation to GGT. Pts w/ CC surgery GGT pre-surgery (N=295) GGT post-surgery (N=1258) Total Partial Colectomy (N=245)N (% total) TC/TP (N=50) N (% total) P-value: partial vs TC/TP^ Total Partial Colectomy (N=1203)N (% total) TC/TP (N=55)N (% total) P-value: partial vs TC/TP^ MLH1 (N=75) 24 (32) 13 (54) 11 (46) 0.001 51 (68) 42 (82) 9 (18) <0.001 MSH2/ EPCAM (N=54) 17 (32) 8 (47) 9 (53) 0.006 37 (69) 29 (78) 8 (22) <0.001 MSH6 (N=49) 13 (27) 11 (85) 2 (15) 1 36 (74) 35 (97) 1 (3) 1 PMS2 (N=51) 6 (12) 3 (50) 3 (50) 0.252 45 (88) 43 (96) 2 (4) 1 LS positive (N=229) 60 (26) 35 (58) 25 (42) <0.001 169 (74) 149 (88) 20 (12) <0.001 LS VUS (N=61) 6 (10) 6 (100) 0 (0) 1 55 (90) 55 (100) 0 (0) 0.526 LS Negative (N=1263) 229 (18) 204 (89) 25 (11) <0.001 1034 (82) 995 (96) 39 (4) 0.006 Note: Excludes pts with RC due to small N. ^Adjusted for multiple testing.

Conversion from radical esophagectomy to definitive chemoradiotherapy after neoadjuvant chemotherapy for advanced esophageal squamous cell carcinoma: Treatment options based on chemotherapy response.

Journal of Clinical Oncology Kiyoshi Narita, Eiji Higaki, Tetsuya Abe et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.408

408 Background: Radical esophagectomy after neoadjuvant chemotherapy (NAC) is the established strategy for resectable advanced esophageal cancer. However, some patients convert to definitive chemoradiotherapy (dCRT) after NAC due to reasons such as their wishes or disease progression, and their prognosis remains uncertain. We aimed to investigate the prognosis of patients who converted to dCRT. Methods: Patients who underwent NAC for resectable advanced esophageal squamous cell carcinoma between 2006 and 2020 were enrolled retrospectively. The prognostic impact of subsequent treatment after NAC, planned surgery or conversion to dCRT, was compared. Results: We analyzed 686 patients, 70 who converted to dCRT (dCRT group) and 616 who underwent surgery (Surg group). The dCRT group had a poorer prognosis than the Surg group, with more advanced tumors and poorer response to NAC. Therefore, further analysis was conducted by categorizing patients as Responders (complete or partial response) and Non-responders (stable or progressive disease) to NAC. Among Responders in the dCRT group, 76.7% achieved a complete response, and the 5-year esophageal preservation survival rate was 66.9%. The 5-year survival rates for Responders were 77.5% and 71.3% in the dCRT and Surg groups. Multivariable analysis showed that dCRT did not worsen prognosis ( P = .706, hazard ratio = 1.13; 95% confidence interval, 0.59 to 2.16). Conversely, in Non-responders, dCRT had a significantly poorer prognosis, with 5-year survival rates of 22.3% and 45.1% in the dCRT and the Surg groups (P < .001). Conclusions: For patients responding to NAC, conversion to dCRT is considered a potential treatment option. The possibility of chemoselection has been suggested in the choice of treatment for esophageal squamous cell carcinoma.

Comparing outcomes for early and late drainage of malignant ascites.

Journal of Clinical Oncology Suriya Baskar, Anuj Sharma, Davin Turku et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.842

842 Background: Malignant ascites (MA) is a common sequela of peritoneal carcinomatosis resulting in significant morbidity and poses substantial management challenges for clinicians. Large volume paracentesis remains the gold standard treatment. The impact of time to drainage of MA is poorly studied. The purpose of this study was to compare clinical outcomes of hospitalized patients with MA that had drainage performed within 48 hours of admission and after 48 hours of admission. Methods: The NIS was queried between the years 2016 and 2020 to identify all adult patients hospitalized with malignant ascites (ICD-10 code R18.0) and had a drainage procedure performed (ICD-10 Procedure code 0W9Gx). These patients were then stratified into an early cohort (<48 hours after admission) and late cohort (>48 hours after admission). Baseline characteristics and clinical outcomes were collected and analyzed using chi squared tests, independent sample t-tests, and binary logistic regression (adjusted for age, gender, and Charlson comorbidity index or CCI). Adjusted Odds ratios (aOR) are presented with 95% Confidence intervals (CI). Results: A total of 129,040 patients were analyzed, with 89,905 (69.7%) hospitalizations in the early cohort and 39,135 (30.3%) in the late cohort. Baseline characteristics were similar between the groups, with no significant differences in age (63.8 vs 63.6, p = .06) or gender distribution (63.6% vs 63.1%, p = .09). However, patients in the early paracentesis group exhibited a lower CCI (9.8 vs 10.2, p<.001). Notably, early paracentesis was associated with significantly improved outcomes, including lower mortality (aOR 0.67, 95% CI 0.64–0.69), reduced incidence of sepsis (aOR 0.67, 95% CI 0.65–0.69), decreased need for transfusions (aOR 0.69, 95% CI 0.66–0.71), lower rates of mechanical ventilation (aOR 0.44, 95% CI 0.42–0.47) and vasopressor use (aOR 0.79, 95% CI 0.73–0.87). Conclusions: Early paracentesis in patients with malignant ascites was found to be associated with significantly improved clinical outcomes, independent of comorbidity burden. These findings underscore the importance of timely intervention to mitigate complications and enhance quality of life. Late ParacentesisN=39,135 EarlyN=89,905 p-value Age (years) 63.6 ± 13.1 63.8 ± 13.0 .06 Gender (% female) 24665 (63.1%) 57120 (63.6%) .09 CCI 10.2 ± 3.1 9.8 ± 3.2 <.001 Mortality 5720 (14.6%) 9030 (10.0%)aOR .67 (.64 - .69) <.001 Sepsis 7675 (19.6%) 12525 (13.9%)aOR .67 (.65 - .69) <.001 Transfusion 5275 (13.5%) 8605 (9.6%)aOR .69 (.66 - .71) <.001 Ventilation 2130 (5.4%) 2190 (2.4%)aOR .44 (.42 - .47) <.001 Vasopressor 770 (2.0%) 1385 (1.5%)aOR .79 (.73 - .87) <.001

Mechanical‐Stimuli‐Driven Pseudo‐Conductive Channels Along Dielectric Heterojunction Interfaces for Mechanoelectric Energy Conversion and Transmission (Adv. Mater. 8/2025)

Advanced Materials Byungseok Seo, Dowon Noh, Yong Choi et al. Feb 01, 2025 DOI: 10.1002/adma.202570061

Pseudotunnel Magnetoresistance in Twisted van der Waals Fe<sub>3</sub>GeTe<sub>2</sub> Homojunctions

Advanced Materials Reiji Obata, Haiming Sun, Kartik Samanta et al. Feb 01, 2025 DOI: 10.1002/adma.202411459

AbstractTwistronics, a novel engineering approach involving the alignment of van der Waals (vdW) integrated two‐dimensional materials at specific angles, has recently attracted significant attention. Novel nontrivial phenomena have been demonstrated in twisted vdW junctions (the so‐called magic angle), such as unconventional superconductivity, topological phases, and magnetism. However, there have been only few reports on integrated vdW layers with large twist angles θt, such as twisted interfacial Josephson junctions using high‐temperature superconductors. Herein, vdW homojunctions of the thin‐magnetic flakes, Fe3GeTe2 (FGT), with large θt ranging from 0° to 90°, without inserting any tunnel barriers are assembled. Nevertheless, these vdW homojunctions exhibit tunnel‐magnetoresistance (TMR) like behavior (pseudo‐TMR (PTMR) effect) with the ratios highly sensitive to the θt values, revealing that the vdW gap at the junction interface between the twisted FGT layers behaves like a tunnel barrier and the θt serves a control parameter for PTMR by drastically varying magnitudes of the lattice‐mismatch and the subsequent appearance of antiferromagnetic (AFM) spin alignment. First‐principles calculations considering vacuum gaps indicate strong dependence of TMR on the θt driven by the sixfold screw rotational symmetry of bulk FGT. The present homojunctions hold promise as a platform for novel AFM spin‐dependent phenomena and spintronic applications.

Pattern and predictors of D3 lymph node station positivity in patients undergoing curative surgery for adenocarcinoma of colon.

Journal of Clinical Oncology Anjaly Mohan, Madhu Muralee, Chandramohan Krishnana Nair et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.137

137 Background: The prognosis and surgical management of colon cancer is intricately related to its lymphatic drainage. The oncological outcome of apical node positivity has been evaluated in different studies with varying results. There is no published regional data on the rate of apical node positivity in colon cancer. An insight into the probability of apical node metastases and the risk factors for the same may help us in prognosticating colon cancer patients better. Methods: This was a prospective observational study conducted at the Regional Cancer Centre Thiruvananthapuram from September 2022 to June 2024. Our primary objective was to determine the prevalence of apical lymph node positivity in patients undergoing surgery for colon cancer with D3 lymphadenectomy. The secondary objectives were to find out the factors associated with the risk of apical node metastasis, the incidence of skip metastases to apical nodes, the adequacy of lymph node harvest and the postoperative complications. Patients undergoing primary surgery for adenocarcinoma of the colon were included. Patients with metastatic disease, synchronous colon or rectal cancers, past history of colonic surgery were excluded. All patients underwent D3 lymphadenectomy along with colectomy depending upon the tumour location. Lymphatic tissue corresponding to the D3 station was retrieved and sent separately after grossing the fresh specimen on the side table in the operating room. Results: A total of 139 patients were included in the study. Fifty two (37.4%) patients had stage III disease, 38.9% had stage II disease and the rest had stage I colon cancer. The mean nodal harvest was 17.86 and mean apical node harvest was 2.04. Node harvest was adequate in 89.21% patients. The apical node positivity rate was 7.19% (10 patients). Skip metastasis to the apical nodes was found in 2 patients. Lymphovascular invasion, number of positive lymph nodes and young age (≤45 years) had a significant correlation with apical node positivity on multivariate analysis. Clavien Dindo grade 3 and above complications were seen in 5.03%. Conclusions: Our study showed an apical node positivity rate of 7.19%, with a skip metastasis rate of 1.4%. This is the first Indian data on apical node positivity rate in colon cancer and its predictors. The prognostic value of apical nodes and the occurrence of skip metastasis to the apical nodes are compelling reasons to advocate D3 dissection, even with relatively low prevalence of apical node positivity.

An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Journal of Clinical Oncology Yunyi Du, Xiaoling Zhang, Ning Ma et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.390

390 Background: Combining epigenetic modulator with PD-1 inhibitor may enhance treatment outcomes in cancer patients. This study aimed to evaluate the efficacy and safety of epigenetic drug decitabine, sintilimab (a PD-1 inhibitor), and chemotherapy in gastric cancer. Methods: In this single-arm, exploratory phase II trial, patients with HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma were enrolled between August 12, 2021, and October 22, 2022. Treatment included low-dose decitabine (10 mg/m² for 5 days), sintilimab (a PD1 inhibitor, 200 mg every 21 days), and XELOX. The primary endpoint was objective response rate (ORR) and second endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The protocol was approved by the ethics committee of the Changzhi Medical College Affiliated Changzhi People's Hospital (No. 2021K002). All patients provided written informed consent form before study participation. The trial is registered with Chinese Clinical Trial, number ChiCTR2100043312. Results: Sixteen patients were initially enrolled, with a median follow-up of 14.8 months. Eleven patients exhibited a PD-L1 combined positive score (CPS) &lt; 5. In the per-protocol sets, 11 patients remained eligible for efficacy analysis. In the intention-to-treat analysis of all 16 patients, 9 achieved partial response and 2 had stable disease, resulting in an ORR of 69% and a DCR of 56%. As of the data cutoff on November 4, 2023, the median PFS was 11.1 months (95% CI, 5.1-not reached) and the median OS was 13.2 months (95% CI, 5.1-not reached). Treatment-related adverse events were generally well-tolerated, with most being grade 1-2. Three patients experienced severe AEs, including one fatal case of grade 4 immune-related pneumonia. Conclusions: The combination of low-dose decitabine, sintilimab, and chemotherapy appears promising strategy for locally advanced or metastatic G/GEJ adenocarcinoma, especially in patients with negative HER2 and low PD-L1 expression. These preliminary findings support further investigations to confirm the benefits and explore the underlying mechanisms. Clinical trial information: ChiCTR2100043312. Objective response and disease response. Full analysis set (n=16) Efficacy analysis set (n=11) Complete response 0 0 Partial response 9 9 Stable disease 2 2 Progressive disease 0 0 Non-evaluable* 5 NA Objective response 9 (56%) 9 (81.8%) Disease control 11 (69%) 11 (100%) NA=not applicable. *Included patients without any post-baseline response assessment.

Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable <i>BRAF</i> <sup>V600E</sup> metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies.

Journal of Clinical Oncology Kelsey Pan, Yunyu Baig, Jason Willis et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.182

182 Background: A BRAF V600E mutation, present in approximately 8-10% of all colorectal cancers (CRC), is a poor prognostic biomarker for patients with metastatic CRC. The BRAF V600E inhibitor encorafenib (E) and the anti-EGFR antibody cetuximab (C) are approved for refractory, BRAF V600E mCRC based upon on overall response rate (ORR) of 20% and median progression-free survival (PFS) of 4.2 months . A single-arm trial adding the anti-PD1 antibody nivolumab (N) to E+C in the same (BRAF-inhibitor naïve) population showed promising efficacy, with an ORR of 50% and median PFS of 7.4 months. We evaluated the efficacy of E+C+N in patients with microsatellite stable (MSS), BRAF V600E mCRC who had progressed on prior E+C. Methods: Patients with MSS, BRAF V600E mCRC with documented prior progression on E+C were eligible for treatment with E (300 mg PO daily), C (500 mg/m 2 q14 days), and N (480 mg IV q28days) were included in the study. Primary endpoint was best overall response by RECIST 1.1. Secondary endpoints were PFS, overall survival (OS), and toxicity (by CTCAE v5). Circulating tumor DNA assessment of molecular alterations in the MAPK pathway in association with response were performed by NGS. Descriptive statistics were used to summarize outcomes. Results: Among the 12 participants, none achieved a radiographic response, and 5 experienced stable disease. Disease control rate was 41.7% (95% CI, 13.8-69.6). Median PFS was 3.7 months (95% CI, 1.7-5.7), and median OS was 8.3 months (NE-NE). Four patients (16.7%) had concomitant MAPK-activating alterations at baseline, and APC , TP53 , and PIK3CA mutations were present in 25.0%, 66.7%, and 33.3% of patients, respectively. The presence of MAPK-activating mutation was not associated with disease progression (odds ratio 1.3; 95% CI 0.11-16; p=0.82). The most common grade 1-2 treatment-related adverse events (AEs) were anemia (N=5), arthralgia (N=5), rash (N=4), headache (N=4), and fatigue (N=3); 1 of the 12 patients experienced a grade 3 small bowel obstruction. Conclusions: In this pilot study, addition of N to E+C did not appear to overcome resistance to prior BRAF + EGFR targeted therapies in patients with MSS, BRAF V600E mCRC. While the addition of immunotherapy has demonstrated promising signal in early-phase clinical trials for this population, the benefit appears unlikely when offered sequentially after progression on BRAF combination therapies. Clinical trial information: NCT04017650 .

Photon‐Induced Ultrafast Multitemporal Programming of Terahertz Metadevices (Adv. Mater. 7/2025)

Advanced Materials Jing Zhang, Jing Lou, Zhuochao Wang et al. Feb 01, 2025 DOI: 10.1002/adma.202570052